Mays Cancer Center conducts only clinical trial in America of a specific drug combination for lethal brain cancer glioblastoma

May 23, 2023

An improvement in 6-month progression-free survival warrants additional study in a larger trial, researchers said. The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM). The Mays Cancer Center, one of the four National Cancer […]

Molecule shows potential to combat treatment resistance in brain tumor glioblastoma

May 17, 2023

Glioblastoma-impacted mice lived longer when treated with combination of molecule drug and chemotherapy agent Glioblastoma (GBM), a highly devastating brain tumor, has long posed challenges as effective treatments have remained elusive. Despite responding initially to treatment, GBM patients often experience therapy resistance leading to low long-term survival rates, with only 7.2% of patients surviving beyond […]

Flies, worms poorly predict drugs’ life span effects in mice, study indicates

April 21, 2023

Doctoral student’s research suggests difficulty of translating longevity interventions from lower species to mammals If a drug extends the life span of worms or flies, is it likely to do the same in mice? Michael Bene, PhD student Not typically based on the existing data, said Michael Bene, a sixth-year doctoral student at The University […]